KR20050010877A - 뇌기능을 개선하는 의약조성물 및 뇌기능을 개선하기 위한방법 - Google Patents
뇌기능을 개선하는 의약조성물 및 뇌기능을 개선하기 위한방법 Download PDFInfo
- Publication number
- KR20050010877A KR20050010877A KR10-2004-7020053A KR20047020053A KR20050010877A KR 20050010877 A KR20050010877 A KR 20050010877A KR 20047020053 A KR20047020053 A KR 20047020053A KR 20050010877 A KR20050010877 A KR 20050010877A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- substituted
- alkyl
- ring
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
화합물(1) 용량(mg/kg) 화합물(2) 용량(mg/kg) 항하이폭시아작용(%) |
대조 - - - 100화합물A1 10 - - 137화합물B1 3 - - 119화합물B2 10 - - 127화합물A1 10 화합물B1 3 211화합물A1 10 화합물B2 10 172 |
화합물(1) 용량(mg/kg) 화합물(2) 용량(mg/kg) 항하이폭시아작용(%) |
대조 - - - 100화합물A2 10 - - 114화합물A3 10 - - 111화합물B1 3 - - 104화합물B2 10 - - 107화합물A2 10 화합물B1 3 168화합물A2 10 화합물B2 10 172화합물A3 10 화합물B1 3 190화합물A3 10 화합물B2 10 149 |
화합물(1) 용량(mg/kg) 화합물(2) 용량(mg/kg) 항하이폭시아작용(%) |
대조 - - - 100화합물C1 100 - - 104화합물C1 300 - - 108화합물C1 300 화합물B1 3 100화합물C2 30 - - 100화합물C2 100 - - 123화합물C2 100 화합물B1 3 111 |
Claims (6)
- 이하의 성분(A) 및 성분(B)를 함유하고, 뇌기능을 개선하는 의약조성물.성분(A): 일반식「식중, R1은, 치환되어 있어도 좋은 복소환식기를; R2는, 수소원자 또는 히드록실기를; R3및 R4는 동일 혹은 다르게 치환되어 있어도 좋은 알킬기, 또는 R3및 R4가 이들이 결합하는 질소원자와 하나로 되어 형성되는 치환되어 있어도 좋은 환상아미노기를; m은 1~5의 정수를; n은 1~6의 정수를 각각 나타낸다.」로 표시되는 알킬에테르유도체 또는 그 염.성분(B) : 아세틸콜린 에스테라제 저해작용을 갖는 (A)성분 이외의 화합물 또는 그 염.
- 제1항에 있어서, 성분(A)의 일반식에 있어서, R1, R2, R3, R4, m 및 n이 이하 (1)~(3)의 어느 하나의 조합으로 이루어진 화합물인 뇌기능을 개선시키는 의약조성물.(1) R1이 할로겐원자, 알킬기, 페닐기로부터 선택되는 기로 치환되어 있어도 좋은 벤조티에닐기 또는 벤조프라닐기; R2가 히드록실기; R3이 알킬기; R4가 알콕시치환페닐기로 치환되어 있어도 좋은 알킬기, 또는 R3및 R4가 이들이 결합하는 질소원자와 하나로 되어 피롤리딘환, 피페리딘, 피페라진환 혹은 몰포린환; m이 1 ; n이 2의 알킬에테르 유도체 또는 그 염.(2) R1이 할로겐원자, 히드록실기로 치환되어 있어도 좋은 알킬기, 알콕시기, 카르복실기, 아미노카르보닐기, 히드록실기, 알킬티오기, 페닐기, 피리딜기로부터 선택되는 기로 치환되어 있어도 좋은 벤조티에닐기 또는 벤조프라닐기; R2가 수소원자; R3이 할로겐원자; 알콕시기 혹은 니트로기로 치환되어 있어도 좋은 페닐기, 보호되어 있어도 좋은 히드록실기, 알킬아미노기, 알키닐기로부터 선택되어 지는 기로 치환되어 있어도 좋은 알킬기; R4가 페닐기로 치환되어 있어도 좋은 알킬기; m이 1; n이 2~3의 알킬에테르유도체 또는 그 염.(3) R1이 할로겐원자, 알킬기, 페닐기로부터 선택되는 기로 치환되어 있어도 좋은 벤조티에닐기 또는 벤조프라닐기; R2가 수소원자; R3또는 R4가 히드록실기, 보호되어 있어도 좋은 아미노기, 알킬아미노기로부터 선택되는 기로 치환되어 있어도 좋은 알킬기, 또는 R3및 R4가 이들이 결합하는 질소원자와 하나로 되어 형성되는 아제티딘환, 피롤리딘환, 피페리딘환, 피페라진환 혹은 몰포린환; m이 1; n이 2~3의 알킬에테르유도체 또는 그 염.
- 제 1항 또는 제2항에 있어서, 성분(B)가 태크린, 도네페질, 리바스티그민, 가란타민, 휴퍼진, 이피다크린, 자나페질, 펜세린, 퀴로스티그민, 간스티그민, 엔사쿠린, T-82로부터 선택되는 1개 이상의 화합물인 뇌기능을 개선시키는 의약조성물.
- 이하의 성분(A) 및 성분(B)를 조합하여 뇌기능 개선을 위하여 사용하는 방법.성분(A); 일반식「식중, R1은, 치환되어 있어도 좋은 복소환식기를; R2는, 수소원자 또는 히드록실기를; R3및 R4는 동일 혹은 다르게 치환되어 있어도 좋은 알킬기, 또는 R3및 R4가 이들이 결합하는 질소원자와 하나로 되어 형성되는 치환되어 있어도 좋은 환상아미노기를; m은 1~5의 정수를; n은 1~6의 정수를, 각각 나타낸다.」로 표시되는 알킬에테르유도체 또는 그 염.성분(B): 아세틸콜린 에스테라제 저해작용을 갖는 (A)성분 이외의 화합물 또는 그 염.
- 제 4항에 있어서, 성분(A)의 일반식에 있어서, R1, R2, R3, R4, m 및 n이 이하 (1)~(3)의 어느 하나의 조합으로 이루어진 화합물인 방법.(1) R1이 할로겐원자, 알킬기, 페닐기로부터 선택되는 기로 치환되어 있어도 좋은 벤조티에닐기 또는 벤조프라닐기; R2가 히드록실기; R3이 알킬기; R4가 알콕시치환페닐기로 치환되어 있어도 좋은 알킬기, 또는 R3및 R4가 이들이 결합하는 질소원자와 하나로 되어 피롤리딘환, 피페리딘, 피페라진환 혹은 몰포린환; m이 1 ; n이 2의 알킬에테르 유도체 또는 그 염.(2) R1이 할로겐원자, 히드록실기로 치환되어 있어도 좋은 알킬기, 알콕시기, 카르복실기, 아미노카르보닐기, 히드록실기, 알킬티오기, 페닐기, 피리딜기로부터 선택되는 기로 치환되어 있어도 좋은 벤조티에닐기 또는 벤조프라닐기; R2가 수소원자; R3이 할로겐원자; 알콕시기 혹은 니트로기로 치환되어 있어도 좋은 페닐기, 보호되어 있어도 좋은 히드록실기, 알킬아미노기, 알키닐기로부터 선택되어 지는 기로 치환되어 있어도 좋은 알킬기; R4가 페닐기로 치환되어 있어도 좋은 알킬기; m이 1; n이 2~3의 알킬에테르유도체 또는 그 염.(3) R1이 할로겐원자, 알킬기, 페닐기로부터 선택되는 기로 치환되어 있어도 좋은 벤조티에닐기 또는 벤조프라닐기; R2가 수소원자; R3또는 R4가 히드록실기, 보호되어 있어도 좋은 아미노기, 알킬아미노기로부터 선택되는 기로 치환되어 있어도 좋은 알킬기, 또는 R3및 R4가 이들이 결합하는 질소원자와 하나로 되어 형성되는 아제티딘환, 피롤리딘환, 피페리딘환, 피페라진환 혹은 몰포린환; m이 1; n이 2~3의 알킬에테르유도체 또는 그 염.
- 제 4항 또는 제 5항에 있어서, 성분(B)가 태크린, 도네페질, 리바스티그민, 가란타민, 휴퍼진, 이피다크린, 자나페질, 펜세린, 퀴로스티그민, 간스티그민, 엔사쿠린, T-82로부터 선택되는 1개 이상의 화합물인 방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPJP-P-2002-00173483 | 2002-06-14 | ||
JP2002173483 | 2002-06-14 | ||
PCT/JP2003/004292 WO2003105830A1 (ja) | 2002-06-14 | 2003-04-03 | 脳機能を改善する医薬組成物および脳機能を改善するための方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050010877A true KR20050010877A (ko) | 2005-01-28 |
KR100935615B1 KR100935615B1 (ko) | 2010-01-07 |
Family
ID=29727916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047020053A KR100935615B1 (ko) | 2002-06-14 | 2003-04-03 | 뇌기능을 개선하는 의약조성물 및 뇌기능을 개선하기 위한방법 |
Country Status (23)
Country | Link |
---|---|
US (3) | USRE42327E1 (ko) |
EP (2) | EP2389937B1 (ko) |
JP (1) | JP4675103B2 (ko) |
KR (1) | KR100935615B1 (ko) |
CN (1) | CN100375619C (ko) |
AT (1) | ATE546140T1 (ko) |
AU (1) | AU2003236364C1 (ko) |
BR (1) | BRPI0311780B8 (ko) |
CA (1) | CA2488120C (ko) |
CY (2) | CY1112958T1 (ko) |
DK (2) | DK1514542T3 (ko) |
ES (2) | ES2685923T3 (ko) |
HU (1) | HUE041842T2 (ko) |
IL (1) | IL165589A (ko) |
MX (1) | MXPA04012534A (ko) |
NO (1) | NO333504B1 (ko) |
NZ (1) | NZ537090A (ko) |
PL (1) | PL217394B1 (ko) |
PT (2) | PT1514542E (ko) |
SI (2) | SI2389937T1 (ko) |
TR (1) | TR201816386T4 (ko) |
WO (1) | WO2003105830A1 (ko) |
ZA (1) | ZA200409901B (ko) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL217872B1 (pl) * | 2001-10-19 | 2014-08-29 | Toyama Chemical Co Ltd | Pochodna eteru alkilowego lub jej sól, stanowiąca 1-{3-[2-(1-benzotiofen-5-ylo)etoksy]propylo}-3-azetydynol lub jego sól |
JP4675103B2 (ja) * | 2002-06-14 | 2011-04-20 | 富山化学工業株式会社 | 脳機能を改善する医薬組成物および脳機能を改善するための方法 |
AU2004229283B2 (en) * | 2003-04-17 | 2009-02-05 | Toyama Chemical Co., Ltd. | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof |
US7435837B2 (en) | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
EP2258358A3 (en) * | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
US8119625B2 (en) * | 2006-04-26 | 2012-02-21 | Toyama Chemical Co., Ltd. | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
PL2011796T3 (pl) * | 2006-04-26 | 2015-03-31 | Toyama Chemical Co Ltd | Induktor neurogenezy lub środek terapeutyczny do stosowania w neuropatii zawierający pochodną eteru alkilowego lub jej sól |
KR20090038471A (ko) * | 2006-08-04 | 2009-04-20 | 토야마 케미칼 컴퍼니 리미티드 | 알킬에테르 유도체 또는 그 염을 함유하는 프로테인키나제 c 활성촉진제 |
US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
EP2287160B1 (en) * | 2008-05-28 | 2014-05-07 | Toyama Chemical Co., Ltd. | Benzothiophene oxide derivative and salt thereof |
ES2694202T3 (es) | 2012-07-12 | 2018-12-19 | Concert Pharmaceuticals, Inc. | Idebenona deuterada |
HUE050400T2 (hu) * | 2014-01-31 | 2020-12-28 | Fujifilm Toyama Chemical Co Ltd | Alkiléter-származékot vagy annak sóját tartalmazó idegi sérülés utáni rehabilitációs hatást fokozó szer |
EP3636262A4 (en) | 2017-06-02 | 2020-06-10 | FUJIFILM Toyama Chemical Co., Ltd. | AGENT FOR PREVENTING OR TREATING ALZHEIMER-LIKE DEMENTIA |
MX2019014306A (es) | 2017-06-02 | 2022-06-09 | Fujifilm Toyama Chemical Co Ltd | Agente para reducir la cantidad de proteina beta amiloide. |
MX2019014310A (es) | 2017-06-02 | 2022-06-10 | Fujifilm Toyama Chemical Co Ltd | Agente para prevenir o tratar atrofia cerebral. |
CA3067455C (en) | 2017-06-02 | 2021-11-23 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating spinocerebellar ataxia |
RU2739199C1 (ru) | 2017-06-02 | 2020-12-21 | ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. | Лекарственное средство для предотврашения или лечения таупатии |
US20200206187A1 (en) * | 2017-07-08 | 2020-07-02 | Rudolph E. Tanzi | Screening platform to identify therapeutic drugs or agents for treatment of alzheimer's disease |
WO2019088083A1 (ja) | 2017-10-30 | 2019-05-09 | 富士フイルム富山化学株式会社 | エモパミル結合タンパク質結合剤およびその利用 |
CN110464834B (zh) * | 2019-09-04 | 2022-12-02 | 北京豪思生物科技股份有限公司 | 铜蓝蛋白联合多奈哌齐的应用 |
KR20220040291A (ko) | 2020-09-23 | 2022-03-30 | 씨엔지바이오 주식회사 | 4-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물 |
KR20220040294A (ko) | 2020-09-23 | 2022-03-30 | 씨엔지바이오 주식회사 | 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL74497A (en) | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
US5177082A (en) | 1985-11-05 | 1993-01-05 | Yu Chao Mei | Huperzines and analogs |
US4663318A (en) | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
JPH0210827A (ja) | 1988-06-29 | 1990-01-16 | Matsushita Electron Corp | 半導体装置の製造方法 |
US5280032A (en) | 1989-02-14 | 1994-01-18 | Toyama Chemical Co., Ltd. | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same |
JP2887492B2 (ja) | 1990-02-05 | 1999-04-26 | 富山化学工業株式会社 | 1,2―エタンジオール誘導体およびその塩 |
NZ232493A (en) | 1989-02-14 | 1992-06-25 | Toyama Chemical Co Ltd | Aryl- or heterocyclyl-substituted 1,2-ethanediol derivatives and pharmaceutical compositions |
JP2913196B2 (ja) | 1989-04-26 | 1999-06-28 | 富山化学工業株式会社 | 1,2−エタンジオール誘導体またはその塩 |
US4914102A (en) * | 1989-09-28 | 1990-04-03 | Hoechst Roussel Pharmaceuticals, Inc. | N-aminocarbamates related to physostigmine, pharmacentical compositions and use |
JP3044055B2 (ja) | 1990-08-09 | 2000-05-22 | 富山化学工業株式会社 | 1,2―エタンジオール誘導体およびその塩 |
JPH0676401B2 (ja) | 1990-10-19 | 1994-09-28 | エスエス製薬株式会社 | キノリン誘導体及びこれを含有する医薬 |
TW197435B (ko) | 1990-11-22 | 1993-01-01 | Takeda Pharm Industry Co Ltd | |
DE4111861A1 (de) | 1991-04-11 | 1992-10-15 | Schwabe Willmar Gmbh & Co | Benzopyranone, verfahren zu ihrer herstellung und verwendung |
JP2925363B2 (ja) | 1991-07-09 | 1999-07-28 | キヤノン株式会社 | 画像処理方法及び装置 |
DE4136288A1 (de) | 1991-11-04 | 1993-05-06 | Troponwerke Gmbh & Co Kg, 5000 Koeln, De | Kombination von calciumantagonisten mit cholinesterase-inhibitoren |
JP3232830B2 (ja) | 1993-11-30 | 2001-11-26 | 三菱電機株式会社 | フレキシブルディスク装置のキャリッジ機構 |
AU700561B2 (en) | 1994-10-25 | 1999-01-07 | Toyama Chemical Co. Ltd. | Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof |
US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
AU1672597A (en) | 1996-02-20 | 1997-09-10 | Toyama Chemical Co. Ltd. | Cerebral function ameliorant containing 1,2-ethanediol derivatives or salts thereof |
HUP9904622A3 (en) | 1996-07-10 | 2001-07-30 | Schering Corp | 1,4-di-sustituted piperidines as muscarinic antagonists |
HUP9904363A3 (en) * | 1996-08-15 | 2000-12-28 | Schering Corp | Piperidine ether muscarinic antagonists and pharmaceutical compositions containing them |
JPH10259126A (ja) | 1997-01-17 | 1998-09-29 | Takeda Chem Ind Ltd | アルツハイマー病治療・予防剤 |
US20030092737A1 (en) | 1997-11-14 | 2003-05-15 | Pierre Maffrand Jean | Combination of active ingredients for the treatment of senile dementia of the Alzheimer type |
CO4980891A1 (es) | 1997-11-14 | 2000-11-27 | Sanofi Sa | Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer |
WO1999031056A1 (fr) * | 1997-12-12 | 1999-06-24 | Toyama Chemical Co., Ltd. | Derives d'ether alcoylique ou leurs sels, et antagonistes du calcium les contenant |
PL196773B1 (pl) | 1999-06-11 | 2008-01-31 | Toyama Chemical Co Ltd | Pochodna N-alkiloksyalkilo-N,N-dialkiloaminy lub jej sole oraz środek zawierający ten związek stosowany do leczenia chorób neurodegeneratywnych |
PL217872B1 (pl) | 2001-10-19 | 2014-08-29 | Toyama Chemical Co Ltd | Pochodna eteru alkilowego lub jej sól, stanowiąca 1-{3-[2-(1-benzotiofen-5-ylo)etoksy]propylo}-3-azetydynol lub jego sól |
JP4675103B2 (ja) | 2002-06-14 | 2011-04-20 | 富山化学工業株式会社 | 脳機能を改善する医薬組成物および脳機能を改善するための方法 |
AU2004229283B2 (en) | 2003-04-17 | 2009-02-05 | Toyama Chemical Co., Ltd. | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof |
PL2011796T3 (pl) | 2006-04-26 | 2015-03-31 | Toyama Chemical Co Ltd | Induktor neurogenezy lub środek terapeutyczny do stosowania w neuropatii zawierający pochodną eteru alkilowego lub jej sól |
US8119625B2 (en) | 2006-04-26 | 2012-02-21 | Toyama Chemical Co., Ltd. | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
-
2003
- 2003-04-03 JP JP2004512734A patent/JP4675103B2/ja not_active Expired - Lifetime
- 2003-04-03 PL PL372934A patent/PL217394B1/pl unknown
- 2003-04-03 EP EP11006318.7A patent/EP2389937B1/en not_active Expired - Lifetime
- 2003-04-03 IL IL165589A patent/IL165589A/en active IP Right Grant
- 2003-04-03 ES ES11006318.7T patent/ES2685923T3/es not_active Expired - Lifetime
- 2003-04-03 KR KR1020047020053A patent/KR100935615B1/ko active IP Right Grant
- 2003-04-03 US US12/683,813 patent/USRE42327E1/en not_active Expired - Lifetime
- 2003-04-03 BR BRPI0311780A patent/BRPI0311780B8/pt not_active IP Right Cessation
- 2003-04-03 ES ES03760132T patent/ES2379948T3/es not_active Expired - Lifetime
- 2003-04-03 PT PT03760132T patent/PT1514542E/pt unknown
- 2003-04-03 EP EP03760132A patent/EP1514542B1/en not_active Expired - Lifetime
- 2003-04-03 PT PT11006318T patent/PT2389937T/pt unknown
- 2003-04-03 SI SI200332578T patent/SI2389937T1/sl unknown
- 2003-04-03 SI SI200332141T patent/SI1514542T1/sl unknown
- 2003-04-03 CA CA2488120A patent/CA2488120C/en not_active Expired - Lifetime
- 2003-04-03 MX MXPA04012534A patent/MXPA04012534A/es active IP Right Grant
- 2003-04-03 AT AT03760132T patent/ATE546140T1/de active
- 2003-04-03 WO PCT/JP2003/004292 patent/WO2003105830A1/ja active Application Filing
- 2003-04-03 NZ NZ537090A patent/NZ537090A/en not_active IP Right Cessation
- 2003-04-03 AU AU2003236364A patent/AU2003236364C1/en not_active Expired
- 2003-04-03 US US10/516,320 patent/US7342043B2/en not_active Ceased
- 2003-04-03 CN CNB038138573A patent/CN100375619C/zh not_active Expired - Lifetime
- 2003-04-03 DK DK03760132.5T patent/DK1514542T3/da active
- 2003-04-03 TR TR2018/16386T patent/TR201816386T4/tr unknown
- 2003-04-03 DK DK11006318.7T patent/DK2389937T3/en active
- 2003-04-03 HU HUE11006318A patent/HUE041842T2/hu unknown
-
2004
- 2004-11-25 NO NO20045158A patent/NO333504B1/no not_active IP Right Cessation
- 2004-12-07 ZA ZA200409901A patent/ZA200409901B/xx unknown
-
2007
- 2007-12-17 US US11/957,832 patent/US7834053B2/en not_active Expired - Lifetime
-
2012
- 2012-05-08 CY CY20121100432T patent/CY1112958T1/el unknown
-
2018
- 2018-08-21 CY CY181100871T patent/CY1120591T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100935615B1 (ko) | 뇌기능을 개선하는 의약조성물 및 뇌기능을 개선하기 위한방법 | |
CA2372668C (en) | Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts | |
EA200501496A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
TNSN04246A1 (fr) | Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation | |
KR960701636A (ko) | 5ht1 길항제로서의 인돌 유도체의 용도(use of indole derivatives as 5ht1 antagonists) | |
KR20110043774A (ko) | 말초 신경병증의 치료를 위한 화합물 | |
JP5042625B2 (ja) | 抗炎症剤として有用なα−アミノアミド誘導体 | |
CZ285633B6 (cs) | Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek | |
JP2001527551A (ja) | Mtpインヒビターと脂溶性ビタミンの組合せおよび該組合せを用いる血清脂質レベルの降下法 | |
US6117890A (en) | Method for treating bipolar disorder | |
CA1209047A (en) | Therapeutic composition containing piracetam analog | |
AU4046897A (en) | Method for treating bipolar disorder | |
JP4366533B2 (ja) | 睡眠障害の治療剤 | |
EE200100193A (et) | 3-(1H-imidasool-4-ülmetüül)-indaan-5-ol'i kasutamine intraspinaalselt, teekasiseselt või epiduraalselt manustatava ravimi tootmises | |
WO1997004797A1 (en) | Use of neuronal calcium channel blockers for the manufacture of a medicament for the treatment of psychoses, schizophrenia and cocaine or amphetamine addiction | |
IE862019L (en) | Pyrrolidinyl-dihydroquinolines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AMND | Amendment | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121130 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20131218 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20141205 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20151201 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20161129 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20181219 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20191219 Year of fee payment: 11 |